Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 47, Issue 8, Pages 2075-2088Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm031044w
Keywords
-
Categories
Ask authors/readers for more resources
Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available